DB:TKDA

Stock Analysis Report

Executive Summary

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products.

Snowflake

Fundamentals

Average dividend payer and fair value.


Similar Companies

Share Price & News

How has Takeda Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.4%

DB:TKDA

3.4%

DE Pharmaceuticals

2.6%

DE Market


1 Year Return

n/a

DB:TKDA

-11.0%

DE Pharmaceuticals

-9.6%

DE Market

No trading data on TKDA.

No trading data on TKDA.


Share holder returns

TKDAIndustryMarket
7 Day-1.4%3.4%2.6%
30 Day-2.8%6.6%-3.0%
90 Day-6.9%14.2%-1.4%
1 Yearn/a-7.9%-11.0%-6.8%-9.6%
3 Yearn/a-10.9%-18.4%11.0%1.5%
5 Yearn/a33.0%11.1%25.6%8.2%

Price Volatility Vs. Market

How volatile is Takeda Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Takeda Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Takeda Pharmaceutical's share price is below the future cash flow value, and at a moderate discount (> 20%).

Takeda Pharmaceutical's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Takeda Pharmaceutical is overvalued based on earnings compared to the DE Pharmaceuticals industry average.

Takeda Pharmaceutical is overvalued based on earnings compared to the Germany market.


Price Based on Expected Growth

Takeda Pharmaceutical is poor value based on expected growth next year.


Price Based on Value of Assets

Takeda Pharmaceutical is good value based on assets compared to the DE Pharmaceuticals industry average.


Next Steps

Future Growth

How is Takeda Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

58.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Takeda Pharmaceutical's revenue is expected to grow by 2.4% yearly, however this is not considered high growth (20% yearly).

Takeda Pharmaceutical's earnings are expected to grow significantly at over 20% yearly.

Takeda Pharmaceutical's revenue growth is positive but not above the Germany market average.

Takeda Pharmaceutical's earnings growth is expected to exceed the Germany market average.

Takeda Pharmaceutical's earnings growth is expected to exceed the low risk savings rate of 0.2%.


Earnings per Share Growth Estimates


Future Return on Equity

Takeda Pharmaceutical is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Takeda Pharmaceutical performed over the past 5 years?

24.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Takeda Pharmaceutical has delivered over 20% year on year earnings growth in the past 5 years.

Takeda Pharmaceutical's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Takeda Pharmaceutical's 1-year earnings growth is negative, it can't be compared to the DE Pharmaceuticals industry average.


Return on Equity

Takeda Pharmaceutical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Takeda Pharmaceutical used its assets less efficiently than the DE Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Takeda Pharmaceutical's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Takeda Pharmaceutical's financial position?


Financial Position Analysis

Takeda Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Takeda Pharmaceutical's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Takeda Pharmaceutical's level of debt (115.9%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (34.1% vs 115.9% today).

Debt is not well covered by operating cash flow (7.2%, less than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 4.2x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.5x debt.


Next Steps

Dividend

What is Takeda Pharmaceutical's current dividend yield, its reliability and sustainability?

5.11%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Takeda Pharmaceutical's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.51%).

Takeda Pharmaceutical's dividend is above the markets top 25% of dividend payers in Germany (4.17%).

Dividends per share have been stable in the past 10 years.

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are not well covered by earnings (0x coverage).


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Takeda Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

4.8yrs

Average management tenure


CEO

Christophe Weber (53yo)

4.3yrs

Tenure

JP¥1,758,000,000

Compensation

Mr. Christophe Weber has been the President and Chief Executive Officer of Takeda Pharmaceutical Company Limited since June 27, 2014 and April 2015 respectively and served as its Chief Operating Officer fr ...


CEO Compensation Analysis

Christophe's remuneration is higher than average for companies of similar size in Germany.

Christophe's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Management Age and Tenure

4.8yrs

Average Tenure

56.5yo

Average Age

The tenure for the Takeda Pharmaceutical management team is about average.


Board Age and Tenure

3.7yrs

Average Tenure

65.5yo

Average Age

The tenure for the Takeda Pharmaceutical board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellJP¥222,79608 Jan 19
JPMorgan Chase & Co, Brokerage and Securities Investments
EntityCompany
Shares13,735
Max PriceJP¥16.22
BuyJP¥4,328,84908 Jan 19
JPMorgan Chase & Co, Brokerage and Securities Investments
EntityCompany
Shares266,866
Max PriceJP¥16.22
SellJP¥374,20213 Dec 18
JPMorgan Chase & Co, Brokerage and Securities Investments
EntityCompany
Shares25,500
Max PriceJP¥14.67
BuyJP¥374,20213 Dec 18
JPMorgan Chase & Co, Brokerage and Securities Investments
EntityCompany
Shares25,500
Max PriceJP¥14.67
SellJP¥1,086,87512 Dec 18
JPMorgan Chase & Co, Brokerage and Securities Investments
EntityCompany
Shares75,000
Max PriceJP¥14.49
BuyJP¥2,939,53511 Dec 18
JPMorgan Chase & Co, Brokerage and Securities Investments
EntityCompany
Shares204,000
Max PriceJP¥14.41
SellJP¥14,172,72711 Dec 18
JPMorgan Chase & Co, Brokerage and Securities Investments
EntityCompany
Shares990,000
Max PriceJP¥14.32
SellJP¥1,769,66010 Dec 18
JPMorgan Chase & Co, Brokerage and Securities Investments
EntityCompany
Shares120,000
Max PriceJP¥14.75
BuyJP¥5,476,64310 Dec 18
JPMorgan Chase & Co, Brokerage and Securities Investments
EntityCompany
Shares370,000
Max PriceJP¥14.80
BuyJP¥3,940,65605 Dec 18
JPMorgan Chase & Co, Brokerage and Securities Investments
EntityCompany
Shares245,000
Max PriceJP¥16.08
BuyJP¥323,34404 Dec 18
JPMorgan Chase & Co, Brokerage and Securities Investments
EntityCompany
Shares20,000
Max PriceJP¥16.17
SellJP¥1,014,11704 Dec 18
JPMorgan Chase & Co, Brokerage and Securities Investments
EntityCompany
Shares61,260
Max PriceJP¥16.55
BuyJP¥2,962,91204 Dec 18
JPMorgan Chase & Co, Brokerage and Securities Investments
EntityCompany
Shares179,000
Max PriceJP¥16.55
BuyJP¥004 Dec 18
JPMorgan Chase & Co, Brokerage and Securities Investments
EntityCompany
Shares262,520
Max PriceJP¥16.55

Ownership Breakdown


Management Team

  • Haruhiko Hirate (62yo)

    Member of Management Board & Corporate Communications and Public Affairs Officer

    • Tenure: 0.0yrs
  • Christophe Weber (53yo)

    President

    • Tenure: 4.3yrs
    • Compensation: JP¥1.76b
  • Seigo Izumo

    Chair of Management Board

    • Tenure: 0.0yrs
  • Iwaaki Taniguchi

    Senior Vice President of Corporate Finance & Controlling Department

    • Tenure: 6.4yrs
  • Andy Plump (54yo)

    President of Research & Development and Director

    • Tenure: 4.2yrs
    • Compensation: JP¥795.00m
  • Masato Iwasaki (61yo)

    President of Japan Pharma Business Unit & Director

    • Tenure: 7.2yrs
    • Compensation: JP¥193.00m
  • Yoshihiro Nakagawa (59yo)

    Global General Counsel

    • Tenure: 4.8yrs
  • Salvatore Alesci

    Member of Management Board and Head of R&D Global Science & Biomedical Policy

    • Tenure: 0.0yrs
  • Costa Saroukos (48yo)

    CFO & Director

    • Tenure: 0.2yrs
  • Takashi Okubo

    Global Head of IR

    • Tenure: 0.0yrs

Board Members

  • Karen Katen (70yo)

    Member of Takeda Global Advisory Board

    • Tenure: 0.0yrs
  • Sidney Taurel (70yo)

    Member of Takeda Global Advisory Board

    • Tenure: 0.0yrs
  • Bruno Francois Angelici (72yo)

    Member of Takeda Global Advisory Board

    • Tenure: 8.8yrs
  • Masahiro Sakane (78yo)

    Chairman of the Board

    • Tenure: 2.2yrs
  • Yasuhiko Yamanaka (63yo)

    Director

    • Tenure: 3.2yrs
    • Compensation: JP¥101.00m
  • Christophe Weber (53yo)

    President

    • Tenure: 4.3yrs
    • Compensation: JP¥1.76b
  • Koji Hatsukawa (68yo)

    External Director

    • Tenure: 3.2yrs
  • Andy Plump (54yo)

    President of Research & Development and Director

    • Tenure: 4.2yrs
    • Compensation: JP¥795.00m
  • Masato Iwasaki (61yo)

    President of Japan Pharma Business Unit & Director

    • Tenure: 7.2yrs
    • Compensation: JP¥193.00m
  • Costa Saroukos (48yo)

    CFO & Director

    • Tenure: 0.2yrs

Company Information

Takeda Pharmaceutical Company Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Takeda Pharmaceutical Company Limited
  • Ticker: TKDA
  • Exchange: DB
  • Founded: 1781
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥5.535t
  • Listing Market Cap: JP¥46.882b
  • Shares outstanding: 1.56b
  • Website: https://www.takeda.com

Number of Employees


Location

  • Takeda Pharmaceutical Company Limited
  • 1-1, Nihonbashi-Honcho 2-chome
  • Chuo-ku
  • Tokyo
  • 103-8668
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TKPH.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 1992
4502TSE (The Tokyo Stock Exchange)YesCommon StockJPJPYJan 1992
0RN3LSE (London Stock Exchange)YesCommon StockGBEURJan 1992
TKDDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1992
TAKNYSE (New York Stock Exchange)SPON ADS EACH REP 0.5 ORD SHSUSUSDMay 2010
TAK NBMV (Bolsa Mexicana de Valores)SPON ADS EACH REP 0.5 ORD SHSMXMXNMay 2010
TKDABST (Boerse-Stuttgart)SPON ADS EACH REP 0.5 ORD SHSDEEURMay 2010
TKDADB (Deutsche Boerse AG)SPON ADS EACH REP 0.5 ORD SHSDEEURMay 2010

Biography

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-dr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/22 22:30
End of Day Share Price2019/08/22 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.